135.49

3.03% 3.98

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $135.49, with a volume of 283.21K. It is up +3.03% in the last 24 hours and up +65.21% over the past month. Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Previous Close:

$131.51

Open:

$132.89

24h Volume:

283.21K

Relative Volume:

0.91

Market Cap:

$1.60B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+5.36%

1M Performance:

+65.21%

6M Performance:

+150.26%

1Y Performance:

+554.54%

1-Day Range:

$130.53

$138.00

1-Week Range:

$127.65

$151.18

52-Week Range:

$18.23

$151.18

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	135.49	1.56B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

Mar 03, 2026

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat

Mar 03, 2026

Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo

Mar 03, 2026

Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada

Mar 03, 2026

Mar 02, 2026

Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia

Mar 02, 2026

Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK

Mar 02, 2026

Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada

Mar 02, 2026

Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat

Mar 02, 2026

Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat

Mar 02, 2026

Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com

Mar 02, 2026

Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com

Mar 02, 2026

Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance

Mar 02, 2026

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire

Mar 02, 2026

LGND: 2025 Results & Focus on Qtorin - Yahoo Finance

Mar 02, 2026

Feb 28, 2026

PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI

Feb 28, 2026

Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail

Feb 28, 2026

Feb 27, 2026

PVLA Stock Surges 86% With A 6-day Winning Spree On Phase 3 Win - Trefis

Feb 27, 2026

Feb 26, 2026

Palvella prices $200M stock offering at $125 per share - Investing.com Australia

Feb 26, 2026

Strategic Update: PVLA Surges Amid New Growth Plans - timothysykes.com

Feb 26, 2026

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up After Analyst Upgrade - MarketBeat

Feb 26, 2026

Palvella Therapeutics shares rise to three-year high on upsized offering - Investing.com UK

Feb 26, 2026

Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge - simplywall.st

Feb 26, 2026

What is Lifesci Capital's Estimate for PVLA FY2026 Earnings? - MarketBeat

Feb 26, 2026

HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings - MarketBeat

Feb 26, 2026